The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the accelerating investment in genomic technologies, Thermo Fisher Scientific has deepened its collaboration with Arcturus Therapeutics for the manufacturing of ARCT-032, a therapy for cystic fibrosis. According to reports, this partnership is designed to expand Thermo Fisher's role in late-stage manufacturing for complex mRNA biologics. The company aims to solidify its position as an end-to-end development partner for the global pharmaceutical industry.
This expansion comes as the mRNA therapy market experiences significant growth, with contract manufacturing organizations (CDMOs) vying for market share against peers such as Lonza and Danaher. Per market data, Thermo Fisher is focusing on diversifying its bioprocessing service revenue to offset the post-pandemic slowdown in laboratory tool sales. The partnership is viewed as an incremental positive for long-term service revenue within the high-growth biotechnology sector.
Sign in to access this content
Sign InRegarding market performance, TMO shares stood at $523.44 (at close July 02, 2026), having traded between a low of $511.98 and a high of $529.15 during that session. Investors are currently monitoring margin sustainability within the laboratory services segment amid fluctuating global demand. With no immediate sector-specific catalysts in the upcoming economic calendar, focus remains on the execution of bioproduction contracts to bolster annual guidance.